Glenmark Pharmaceuticals Ltd.
GLENMARK · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹1,755.11.
Piotroski F-score 7/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%14.1%
- ✓Low debt (D/E < 0.5)0.06x
- ✓Positive free cash flow
- ✓Revenue growth > 10%14%
- ✓Earnings growing6575%
- ✕Net margin ≥ 10%8.0%
- ✓Current ratio > 1.51.77
- ✓Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✕Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 5.65
- ✓Piotroski ≥ 77/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Financially solid — Altman Z 5.65.
- •High Piotroski quality score (7/9).
Opportunities
- •Earnings growing (6575% YoY).
- •Revenue growing (14% YoY).
- •Trading in our value buy zone versus sector peers.
About Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertension, central nervous system, cardiology, diabetes, contraceptives, gynecology, gas
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.